(-)-Indolactam V

90365-57-4

C17H23N3O2

DMSO : 50 mg/mL (165.90 mM; Need ultrasonic)

TGF-beta/Smad; Epigenetics

(-)-Indolactam V is a PKC activator, with K_is of 3.36 nM, 1.03 uM for eta-CRD2 (PKCeta surrogate peptide), gamma-CRD2 (PKCgamma surrogate peptide), and K_ds of 5.5 nM (eta-C1B), 7.7 nM (epsilon-C1B), 8.3 nM (delta-C1B), 18.9 nM (beta-C1A-long), 20.8 nM (alpha-C1A-long), 137 nM (beta-C1B), 138 nM (gamma-C1A), 213 nM (gamma-C1B), and has antitumor activity. IC50 & Target: Ki: 3.36 nM (eta-CRD2 (PKCeta surrogate peptide)), 1.03 uM (gamma-CRD2 (PKCgamma surrogate peptide))^[1]
Kd: 5.5 nM (eta-C1B), 7.7 nM (epsilon-C1B), 8.3 nM (delta-C1B), 18.9 nM (beta-C1A-long), 20.8 nM (alpha-C1A-long), 137 nM (beta-C1B), 138 nM (gamma-C1A), 213 nM (gamma-C1B)^[2] In Vitro: (-)-Indolactam V is a PKC activator, with K_is of 3.36 nM, 1.03 uM for eta-CRD2 (PKCeta surrogate peptide), gamma-CRD2 (PKCgamma surrogate peptide), and has antitumor activity^[1]. (-)-Indolactam V shows K_ds of 5.5 nM (eta-C1B), 7.7 nM (epsilon-C1B), 8.3 nM (delta-C1B), 18.9 nM (beta-C1A-long), 20.8 nM (alpha-C1A-long), 137 nM (beta-C1B), 138 nM (gamma-C1A), 213 nM (gamma-C1B), respectively^[2]. (-)-Indolactam V (20 nM-5 uM) dose-dependently affects multiple hESC lines, such as HUES 2, 4 and 8. (-)-Indolactam V also increases the mRNA levels of Pdx1, HNF6, PTF1A, SOX9, HB9 and PROX1. In addition, (-)-Indolactam V (300 nM) functions in both mouse and human cells and confirms that some signals for pancreatic development^[3].